Financial Conflicts of Interest in PHS-funded Research

In accordance with PHS regulations, this web page provides public access to information pertaining to Financial Conflicts of Interest (FCOI) of PHS-funded research. The information on this web page will remain available for three (3) years after its most recent update. Information required by PHS regulation:

  1. the covered individual’s name;
  2. the covered individual’s title and role with respect to the research;
  3. the name of the entity in which the financial interest is held;
  4. the nature of the financial interest that constitutes a financial conflict of interest; and
  5. the approximate value of the financial interest by range or, if the dollar value cannot be determined by reference to public prices or other reasonable measures of fair market value, a statement to that effect.

A management plan is established in cooperation with the Covered Individual to address the FCOI per University policy. The information posted on this website is derived from the management plan.

The information posted on this website is subject to updates on at least an annual basis and within 60 days of the University’s identification of the FCOI. The information on this website was last updated on January 10, 2017.

Randolph Bias, Ph.D.

Title and Role with Respect to the Research
Professor and Co-Investigator

Name of Entity in which the Financial Interest is Held
The Usability Team

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The covered individual is a principal in The Usability Team, a business that consults on the usability of software and web page design. The business interests of The Usability Team overlap with the covered individual's area of research.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Return to top.

Robert Cabrera, Ph.D.

Title and Role with Respect to the Research
Research Scientist and  Investigator

Name of Entity in which the Financial Interest is Held
TeratOmic Consulting, LLC.

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual received monetary payment from TeratOmic Consulting, LLC, a company that provides expert opinion for legal matters related to toxic compounds that cause birth defects. The business interests of TeratOmic Consulting, LLC overlap with the Covered Individual’s area of research.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
$40,000 – $59,999

Return to top.

Kenneth Diller, Ph.D.

Title and Role with Respect to the Research
Professor and Principal Investigator

Name of Entity in which the Financial Interest is Held
Bioheat Transfer, LLC, Cool Core Biomedical Technologies, LLC, Mercury Biomed, LLC

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual is founder and President of Bioheat Transfer, LLC, and Cool Core Biomedical Technologies. He is also the Chief Scientific Officer and a Member of Board of Directors at Mercury Biomed, LLC. The Covered Individual holds equity in all three companies. The Covered Individual also holds the intellectual property rights and/or may receive royalty payments related to patented technologies that are related his area of research. The results of the research projects may increase the value of his patents.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Return to top.

Richard Finnell, Ph.D.

Title and Role with Respect to the Research
Professor and Principal Investigator

Name of Entity in which the Financial Interest is Held
TeratOmic Consulting, LLC.

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual is CEO of TeratOmic Consulting, LLC, a company that provides expert opinion for legal matters related to toxic compounds that cause birth defects. The business interests of TeratOmic Consulting, LLC overlap with the Covered Individual’s area of research.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
$80,000 – $99,999

Return to top.

George Georgiou, Ph.D.

Title and Role with Respect to the Research
Professor and Principal Investigator

Name of Entity in which the Financial Interest is Held
GMA, LLC and Aeglea, LLC

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual holds equity interest in GMA, LLC. The Covered Individual conducts sponsored research on intellectual property that has been assigned to GMA, LLC. The Covered Individual is co-founder, a member of the board of directors, and holds equity interest in Aeglea, LLC.The Covered Individual is inventor of technology licensed to Aeglea, LLC through GMA, LLC. The Covered Individual receives research funding from Aeglea, LLC. The business interests of GMA, LLC and Aeglea, LLC overlap with the Covered Individual’s area of research.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
51-100% equity interest; value cannot be readily determined through reference to public prices or other reasonable measures of fair market value (GMA, LLC).

11-20% equity interest; value cannot be readily determined through reference to public prices or other reasonable measures of fair market value (Aeglea, LLC).

Return to top.

Ning Jiang, Ph.D.

Title and Role with Respect to the Research
Assistant Professor and Principal Investigator

Name of Entity in which the Financial Interest is Held
“Measurement and Comparison of Immune Diversity by High-throughput Sequencing.”

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual is in an agreement to receive royalties from the licensing of intellectual property that overlaps with her area of research involving systems immunology.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Return to top.

Miyong Kim, Ph.D.

Title and Role with Respect to the Research
Professor and Principal Investigator

Name of Entity in which the Financial Interest is Held
Korean Resource Center

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual’s covered family member is a paid officer at the Korean Resource Center. The Korean Resource Center is involved in research of which the Covered Individual is Principal Investigator and primary grantee of federal funding. Grant funds that support the Covered Individual’s research are subawarded to the Korean Resource Center.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
$100,000 – 150,000

Return to top.

Alan Lambowitz, Ph.D.

Title and Role with Respect to the Research
Director, Professor and Principal Investigator

Name of Entity in which the Financial Interest is Held
InGex, LLC.

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual and a Covered Family Member hold equity interest in InGex, LLC. The Covered Individual conducts research on intellectual property involving targetron technology and group II intron reverse transcriptases that is licensed by the University to InGex, LLC for commercialization.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
31-45 % equity interest; value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Return to top.

Robert Messing, MD

Title and Role with Respect to the Research
Professor and Principal Investigator

Name of Entity in which the Financial Interest is Held
University of California, San Francisco

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual is co-inventor on a composition-of-matter patent owned by The University of California, San Francisco titled, "PKC-Epsilon Inhibitors". Some compounds in the patent are used in experiments planned in research projects that are funded or proposed for funding by the National Institutes of Health.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Return to top.

John Pearce, Ph.D.

Title and Role with Respect to the Research
Professor and Principal Investigator

Name of Entity in which the Financial Interest is Held
Admittance Technologies, Inc.

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual holds equity interest in and is a scientific advisor for Admittance Technologies, Inc., a company that develops innovative electrical engineering solutions to improve the quality of life of patients with heart disease. The business interests of Admittance Technologies, Inc. overlap with some, but not all of the Covered Individual's research.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
3% equity interest; value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Return to top.

Hugh Smyth, Ph.D.

Title and Role with Respect to the Research
Associate Professor and Principal Investigator

Name of Entity in which the Financial Interest is Held
Respira Therapeutics, Inc.

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual is a Consulting Chief Scientist to Respira Therapeutics, Inc. and an inventor of technologies used by Respira Therapeutics, Inc. The Covered Individual receives reimbursement for travel relating to consulting for Respira Therapeutics, Inc. The business interests of Respira Therapeutics, Inc. overlap with the Covered Individual’s area of research.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
$10,000-$19,999

Return to top.

Everett Stone, Ph.D.

Title and Role with Respect to the Research
Research Scientist and Principal Investigator

Name of Entity in which the Financial Interest is Held
GMA, LLC and Aeglea, LLC

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual holds equity interest in GMA, LLC and Aeglea, LLC. The Covered Individual conducts sponsored research on intellectual property that has been assigned to GMA, LLC. Aeglea, LLC develops protein drugs related to the technology owned by GMA, LLC. The Covered Individual is a consultant for engineering, development, and manufacture of therapeutic proteins for Aeglea, LLC. The business interests of GMA, LLC and Aeglea, LLC overlap with the Covered Individual’s area of research.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
6-10% equity interest; value cannot be readily determined through reference to public prices or other reasonable measures of fair market value. (GMA, LLC).

5% equity interest; value cannot be readily determined through reference to public prices or other reasonable measures of fair market value. (Aeglea, LLC).

Return to top.

Laura Suggs, Ph.D.

Title and Role with Respect to the Research
Associate Professor and Principal Investigator

Name of Entity in which the Financial Interest is Held
MicroMulson

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual is a member of the Board of Directors at MicroMulson, a company whose business interests involve a microgel that provides binding and controlled release of a variety of growth factors for cell culture applications. The business interests of MicroMulsion overlap with her area of research and potentially compete with the business interests of companies that fund other research projects.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Return to top.

Jonathan Valvano, Ph.D.

Title and Role with Respect to the Research
Professor and Principal Investigator

Name of Entity in which the Financial Interest is Held
Admittance Technologies, Inc.

Nature of the Financial Interest that Constitutes a Financial Conflict of Interest:
The Covered Individual holds equity interest in and travel costs were reimbursed or sponsored by Admittance Technologies, Inc. The business interests of Admittance Technologies, Inc. overlap with the Covered Individual's research. Additionally, the Covered Individual has agreements to share in royalties related to intellectual property rights from patented technologies that are related to the Covered Individual's area of research.

Approximate Value of the Financial Interest by Range, or If the Dollar Value Cannot Be Determined by Reference to Public Prices or Other Reasonable Measures of Fair market Value, a Statement to that Effect
11-20% equity interest; value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

Return to top.